Clover Biopharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Clover Biopharmaceuticals is Joshua G. Liang, benoemd in Dec2020, heeft een ambtstermijn van 3.92 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 17.39M, bestaande uit 25.2% salaris en 74.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.6% van de aandelen van het bedrijf, ter waarde HK$ 5.81M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 3.2 jaar.

Belangrijke informatie

Joshua G. Liang

Algemeen directeur

CN¥17.4m

Totale compensatie

Percentage CEO-salaris	25.2%
Dienstverband CEO	3.9yrs
Eigendom CEO	1.6%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth

Mar 17

Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?

Nov 29

Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?

Aug 31

We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely

Apr 28

Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate

Feb 05

Analyse CEO-vergoeding

Hoe is Joshua G. Liang's beloning veranderd ten opzichte van Clover Biopharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥884m
Mar 31 2024	n/a	n/a	-CN¥511m
Dec 31 2023	CN¥17m	CN¥4m	-CN¥139m
Sep 30 2023	n/a	n/a	-CN¥402m
Jun 30 2023	n/a	n/a	-CN¥665m
Mar 31 2023	n/a	n/a	-CN¥2b
Dec 31 2022	CN¥30m	CN¥8m	-CN¥2b
Sep 30 2022	n/a	n/a	-CN¥4b
Jun 30 2022	n/a	n/a	-CN¥6b
Mar 31 2022	n/a	n/a	-CN¥6b
Dec 31 2021	CN¥15m	CN¥8m	-CN¥6b
Dec 31 2020	CN¥4m	CN¥4m	-CN¥913m

Compensatie versus markt: De totale vergoeding ($USD 2.40M ) Joshua G. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 233.55K ).

Compensatie versus inkomsten: De vergoeding van Joshua G. is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Joshua G. Liang (31 yo)

3.9yrs

Tenure

CN¥17,390,000

Compensatie

Mr. Joshua G. Liang is Executive Director and Chief Executive Officer at Clover Biopharmaceuticals, Ltd. since December 25, 2020. Mr. Liang is primarily responsible for leading the management and operation...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peng Liang	Founder	6.1yrs	CN¥5.83m	16.18% HK$ 58.8m
Joshua G. Liang	CEO & Executive Director	3.9yrs	CN¥17.39m	1.6% HK$ 5.8m
Yang Li	Chief Technology Officer	1.8yrs	geen gegevens	geen gegevens
Htay Htay Han	Chief Medical Officer of Vaccine	3.8yrs	geen gegevens	geen gegevens
Berry Michael	Chief Technical Operation Officer	no data	geen gegevens	geen gegevens
Abigail Bracha	Senior Vice President of Corporate Strategy & Business Development	2.9yrs	geen gegevens	geen gegevens
Tracy Wang	Senior Vice President of Head of Regulatory Affairs	2.9yrs	geen gegevens	geen gegevens
Nicholas Jackson	President of Global Research & Development	2.8yrs	geen gegevens	geen gegevens
LiongHo Chua	President of Greater China	2.6yrs	geen gegevens	geen gegevens
Igor Smolenov	Executive Vice President of Global Clinical Development Vaccines	2.4yrs	geen gegevens	geen gegevens
Nicolas Burdin	Executive VP & Global Head of Research	2.3yrs	geen gegevens	geen gegevens
Francois Verdier	Head of Global Regulatory Affairs	2.3yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2197 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peng Liang	Founder	6.1yrs	CN¥5.83m	16.18% HK$ 58.8m
Joshua G. Liang	CEO & Executive Director	3.9yrs	CN¥17.39m	1.6% HK$ 5.8m
Jeffrey S. Farrow	Independent Non-Executive Director	3.2yrs	CN¥3.20m	0.031% HK$ 113.3k
Ralf Leo Clemens	Non-Executive Director	2.4yrs	CN¥1.49m	0.063% HK$ 230.5k
Xiaodong Wang	Non-Executive Director	3.7yrs	CN¥3.18m	2.19% HK$ 8.0m
Donna Marie Ambrosino	Non-Executive Director	2.4yrs	CN¥907.00k	0.015% HK$ 53.1k
Thomas Edward Leggett	Independent Non-Executive Director	3.2yrs	CN¥3.31m	0.031% HK$ 113.3k
Xiaobin Wu	Independent Non-Executive Director	3.2yrs	CN¥3.28m	0.031% HK$ 113.3k
Xiang Liao	Independent Non-Executive Director	3.2yrs	CN¥3.26m	0.031% HK$ 113.3k

3.2yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2197 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Clover Biopharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Clover Biopharmaceuticals, Ltd., Annual General Meeting, Jun 20, 2024

Founder recently bought HK$1.2m worth of stock

CEO & Executive Director recently bought HK$595k worth of stock

Founder recently bought HK$1.0m worth of stock

Less than half of directors are independent

Clover Biopharmaceuticals, Ltd. Announces Board Changes

Recent updates

Clover Biopharmaceuticals, Ltd. Announces Positive Additional Immunogenicity and Safety Data in Older Adult & Elderly Subjects from Its Phase I Trial Evaluating SCB-1019

New major risk - Share price stability

First half 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.53 profit in 1H 2023)

New major risk - Financial position

Clover Biopharmaceuticals, Ltd. to Report Q2, 2024 Results on Aug 27, 2024

Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults

Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding

Clover Biopharmaceuticals, Ltd., Annual General Meeting, Jun 20, 2024

New major risk - Negative shareholders equity

Clover Biopharmaceuticals, Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

Clover Biopharmaceuticals, Ltd. Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia

Clover Biopharmaceuticals, Ltd. Initiates Phase Clinical Trial for RSV Vaccine Candidate

New minor risk - Market cap size

Clover Biopharmaceuticals, Ltd. Completes Biologic License Application for Its Seasonal Influenza Vaccine in Brazil

New minor risk - Market cap size

Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China

Founder recently bought HK$1.2m worth of stock

CEO & Executive Director recently bought HK$595k worth of stock

New major risk - Financial position

Clover Biopharmaceuticals, Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Clover Biopharmaceuticals, Ltd. Provides Updates on Business and R&D Pipeline Development

Clover Biopharmaceuticals, Ltd. announced that it has received $48.882447 million in funding

Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth

Clover Launches Covid-19 Booster Vaccine in the People’s Republic of China

Clover Biopharmaceuticals, Ltd. Provides Updates on COVID-19 Vaccine Commercial Launch

Founder recently bought HK$1.0m worth of stock

Clover Biopharmaceuticals, Ltd. Announces COVID-19 Vaccine, SCB-2019 (CpG 1018/ Alum), Has Been Evaluated by Relevant Authorities of the People's Republic of China and Included for Emergency Use in the PRC

Clover Biopharmaceuticals, Ltd. Announces Vaccine Candidate Reduced Household Transmission of SARS-COV-2 by 84% in Study Published in Clinical Infectious Diseases

Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Clover Biopharmaceuticals, Ltd. Announces Board Changes

Founder recently bought HK$636k worth of stock

Founder recently bought HK$421k worth of stock

Founder recently bought HK$1.2m worth of stock

Clover Biopharmaceuticals, Ltd.'s COVID-19 Vaccine Candidate Receives European Union GMP Certificate

Clover Biopharmaceuticals, Ltd. Announces Positive Data from Its Ongoing Phase 3 Study Evaluating IT’S SCB-2019

Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?

Clover Biopharmaceuticals, Ltd.’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5

Clover Announces Positive Phase 2/3 Results in Adolescents for Its Covid-19 Vaccine

Clover Biopharmaceuticals, Ltd. to Report First Half, 2022 Results on Aug 23, 2022

Clover Biopharmaceuticals, Ltd. Announces Executive Changes

Clover Biopharmaceuticals, Ltd. Announces New Positive Clinical Data in Individuals Vaccinated with A Third Dose of Scb-2019 as A Homologous Booster Against the Omicron Variant

Clover Biopharmaceuticals, Ltd. Appoints Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to Board of Directors

Clover Biopharmaceuticals, Ltd. Doses First Patient with Scb-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia

Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines

Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 1 Trial with SCB-2020S, Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate

We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely

Less than half of directors are independent

Clover Biopharmaceuticals, Ltd. Announces Board Changes

Clover Biopharmaceuticals, Ltd., Annual General Meeting, May 27, 2022

Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate

Clover Biopharmaceuticals, Ltd. Appoints Nicholas Jackson as President of Global Research and Development

Clover Biopharmaceuticals, Ltd. Announces Publication in the Lancet Showing that SCB-2019 (CPG 1018/ALUM) in Phase 2/3 Clinical Trial Demonstrates Efficacy Against Entire Severity Spectrum of COVID-19

Clover Biopharmaceuticals, Ltd. Dosing of First Participants with Homologous Booster Dose of Covid-19 Vaccine Candidate in Spectra

Clover Biopharmaceuticals, Ltd. and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human Trail-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis

Clover Biopharmaceuticals, Ltd. Initiates Investigator-Led, Phase 2 Trial to Evaluate the Immunogenicity and Safety of Heterologous and Homologous COVID-19 Booster Vaccines

Less than half of directors are independent

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd